Metformin extended release: Metformin gastric retention, metformin GR, metformin XR

Drugs in R and D

Volumn 6, Issue 5, 2005, Pages 316-319

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

GLIBENCLAMIDE; METFORMIN; METFORMIN GR; ANTIDIABETIC AGENT;

AREA UNDER THE CURVE; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG DOSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FORMULATION; DRUG INDUSTRY; DRUG LABELING; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL DISEASE; HEADACHE; HUMAN; LOOSE FECES; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TASTE DISORDER; ENTERIC COATED TABLET;

CLINICAL TRIALS; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; TABLETS, ENTERIC-COATED;

EID: 33644831414     PISSN: 11745886     EISSN: 11745886     Source Type: Journal    
DOI: 10.2165/00126839-200506050-00009     Document Type: Review

References (12)

1. Biovail Corporation, Depomed Inc. Biovail and Depomed Submit NDA for Glumetza - Metformin GR; Submission Includes 500mg and 1000mg Dosages. Media Release: 28 Apr 2004. Available from URL: http://www.depomedinc.com
2. Biovail Corporation, Depomed Inc. Biovail, Depomed Receive Approvable Letter from FDA for Extended-Release Glumetza for Type II Diabetes. Media Release: 1 Mar 2005. Available from URL: http://www.biovail.com
3. Biovail Corporation, Depomed Inc. Biovail, Depomed Receive FDA Approval for Extended-Release Glumetza for Type II Diabetes; Enhanced Formulation to Offer Physicians Potential Advantages. Media Release: 3 Jun 2005. Available from URL: http://www.biovail.com
4. Depomed Inc. Depomed Receives $25 Million from Biovail. Media Release: 6 Jul 2005. Available from URL: http://www.depomedinc.com
5. Biovail Corporation, Depomed Inc. Depomed, Biovail Update Status of Glumetza NDA. Media Release: 13 Apr 2005. Available from URL: http://www.depomedinc.com
6. Biovail Corporation, Depomed Inc. Biovail, Depomed Announce Glumetza NDA Accepted by FDA. Media Release: 24 Jun 2004. Available from URL: http://www.biovail.com
7. Biovail Corporation. Biovail, Depomed Announce Regulatory Approval of Glumetza to Treat Type II Diabetes in Canada. Media Release: 1 Jun 2005. Available from URL: http://www.biovail.com
8. Depomed Inc. Depomed Expands Patent Portfolio for Drug Delivery Technology. Media Release: 11 May 2004. Available from URL: http://www. depomedinc.com
9. Biovail Corporation, Depomed Inc. Biovail and Depomed Announce Glumetza NDS Acceptance. Media Release: 10 Aug 2004. Available from URL: http://www.biovail.com
10. Gorsline J, Gusler G, Levy G, et al. Pharmacokinetics of metformin gastric-retentive tablets in healthy volunteers. Journal of Clinical Pharmacology 41: 655-661, Jun 2001
11. Biovail Corporation, DepoMed Inc. DepoMed and Biovail Report Positive Phase III Clinical Results for Metformin GR Extended Release Formulation. Media Release: 3 Feb 2003. Available from URL: http://www.depomedinc.com
12. Biovail Corporation, Depomed Inc. Depomed and Biovail Report Positive Phase III Results with Metformin GR for Diabetes. Media Release: 10 Dec 2003. Available from URL: http://www.depomedinc.com